2023
Guidelines for best practices in monitoring established coeliac disease in adult patients
Elli L, Leffler D, Cellier C, Lebwohl B, Ciacci C, Schumann M, Lundin K, Chetcuti Zammit S, Sidhu R, Roncoroni L, Bai J, Lee A, Dennis M, Robert M, Rostami K, Khater S, Comino I, Cebolla A, Branchi F, Verdu E, Stefanolo J, Wolf R, Bergman-Golden S, Trott N, Scudeller L, Zingone F, Scaramella L, Sanders D. Guidelines for best practices in monitoring established coeliac disease in adult patients. Nature Reviews Gastroenterology & Hepatology 2023, 21: 198-215. PMID: 38110546, DOI: 10.1038/s41575-023-00872-2.Peer-Reviewed Original ResearchConceptsCoeliac diseaseLevel of evidenceLife-long gluten-free dietGluten-free dietMucosal atrophyAdult patientsCirculating autoantibodiesFollow-upGenetic predispositionImmunological diseasesRecommendations AssessmentMonitoring patientsClinical guidelinesEvidence levelPatientsConsumption of glutenDiagnosisDiseaseGuidelinesScientific societiesCeDAutoantibodiesGastroenterologistsAtrophyStandardizing Randomized Controlled Trials in Celiac Disease: An International Multidisciplinary Appropriateness Study
Lebwohl B, Ma C, Lagana S, Pai R, Baker K, Zayadi A, Hogan M, Bouma G, Cellier C, Goldsmith J, Lundin K, Pinto-Sanchez M, Robert M, Rubio-Tapia A, Sanders D, Schaeffer D, Semrad C, Silvester J, Verdú E, Verma R, Wu T, Feagan B, Crowley E, Jairath V, Murray J. Standardizing Randomized Controlled Trials in Celiac Disease: An International Multidisciplinary Appropriateness Study. Gastroenterology 2023, 166: 88-102. PMID: 37704112, DOI: 10.1053/j.gastro.2023.08.051.Peer-Reviewed Original ResearchConceptsRandomized controlled trialsSecondary patient-reported outcome measuresOutcome measuresRandomized controlled trial designPatient-reported outcome measuresControlled trialsGluten challengeStandard Randomized Controlled TrialPatient-reported outcomesGluten-free dietReversal of histological changesMethods studyCeliac diseaseEligibility criteriaHistological end pointsPrevention of relapseEffective pharmacological optionsAppropriate studiesTrial outcomesExclusion criteriaClinical trial designTrial designTreatment of celiac diseasePediatric patientsPharmacological options
2000
The Histologic Spectrum and Clinical Outcome of Refractory and Unclassified Sprue
Robert M, Ament M, Weinstein W. The Histologic Spectrum and Clinical Outcome of Refractory and Unclassified Sprue. The American Journal Of Surgical Pathology 2000, 24: 676-687. PMID: 10800986, DOI: 10.1097/00000478-200005000-00006.Peer-Reviewed Original ResearchConceptsSmall bowel biopsyBowel biopsyCollagenous sprueUnclassified sprueRefractory patientsCeliac diseaseNormal duodenal biopsiesResidual mucosal abnormalityResponsive celiac diseaseSetting of malabsorptionGluten-free dietTotal parenteral nutritionGroup of patientsLong-term followB-cell lymphomaSubtle histologic changesMucosal thinningPersistent malabsorptionDuodenal biopsiesParenteral nutritionRefractory courseRefractory diseaseNonspecific findingsClinical outcomesChronic inflammation